{"name":"Institut fur Klinische Forschung, Germany","slug":"institut-fur-klinische-forschung-germany","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBkeWotNGFkaFFDRHFGRU9ZYUI1U0R3eXFNdkJNZnpGZDd1a1RZQk9jTGl1NTRPWVM5QXY4VWtoVXJlTHhBVFFBT0dqUVEyYmtENzhoa0JialJiWGM?oc=5","date":"2023-05-11","type":"pipeline","source":"EurekAlert!","summary":"Expansion of cell-to-cell communication drives the early development of pancreatic cancer, new research in mice finds - EurekAlert!","headline":"Expansion of cell-to-cell communication drives the early development of pancreatic cancer, new research in mice finds - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9aMEJ2aG5sZmFqNnNzX3J4TGo4dlhlS0VvcDNxWUhNN2R5cXNCSlRseWwzdjNEc01PS19IdmgxTzVQbVNkZHhPbEZOc1dlQWVyLXc?oc=5","date":"2013-03-21","type":"pipeline","source":"nature.com","summary":"Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril | Journal of Human Hypertension - nature.com","headline":"Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-convert","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}